A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 17, Issue 5-6, 2016, Pages 426-435

  Shefner, Jeremy M ^a   Wolff, Andrew A ^b   Meng, Lisa ^b   Bian, Amy ^b   Lee, Jacqueline ^b   Barragan, Donna ^b   Andrews, Jinsy A ^b  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b Cytokinetics Inc   (United States)

Author keywords

amyotrophic lateral sclerosis; Clinical trial; tirasemtiv; troponin activator

Indexed keywords

PLACEBO; TIRASEMTIV; CK-2017357; IMIDAZOLE DERIVATIVE; PYRAZINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ACUTE RESPIRATORY FAILURE; ADULT; AGITATION; AMYOTROPHIC LATERAL SCLEROSIS; AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE; ANGINA PECTORIS; ARTICLE; ASPIRATION PNEUMONIA; ASTHENIA; ATRIAL FIBRILLATION; BLOOD CLOTTING DISORDER; CEREBROVASCULAR ACCIDENT; CONFUSION; CONSTIPATION; CONTROLLED STUDY; CONTUSION; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DELIRIUM; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; DYSPHAGIA; EVENING DOSAGE; FATIGUE; FEMALE; HEADACHE; HEART INFARCTION; HUMAN; INSOMNIA; KIDNEY INFECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MAXIMUM HANDGRIP FATIGUE; MAXIMUM VOLUNTARY VENTILATION; MENTAL DISEASE; MIDDLE AGED; MORNING DOSAGE; MUSCLE SPASM; MUSCLE STRENGTH; MUSCLE WEAKNESS; NAUSEA; NERVOUS SYSTEM PARAMETERS; NEUROLOGIC DISEASE ASSESSMENT; PARESIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RHINOPHARYNGITIS; SLOW VITAL CAPACITY; SNIFF NASAL INSPIRATORY PRESSURE; SOMNOLENCE; SPINAL COLUMN STENOSIS; SPINAL HEMATOMA; SPINE DISEASE; STENOSIS; SUICIDAL IDEATION; TREATMENT WITHDRAWAL; TREMOR; AGE; AGED; CLINICAL TRIAL; DRUG EFFECTS; FOLLOW UP; HAND STRENGTH; INTERNATIONAL COOPERATION; MULTICENTER STUDY; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; VITAL CAPACITY;

ADULT; AGE FACTORS; AGED; AMYOTROPHIC LATERAL SCLEROSIS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HAND STRENGTH; HUMANS; IMIDAZOLES; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; MUSCLE STRENGTH; PYRAZINES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84961216042     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2016.1148169     Document Type: Article

References (23)

1. A.J.Russell, J.J.Hartman, A.C.Hinken, et al. Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012;18:452–5.
2. R.Hansen, K.G.Saikali, W.Chou, et al. Tirasemtiv amplifies skeletal muscle response to nerve activation in humans. Muscle & Nerve. 2014:50:925–31.
3. D.T.Hwee, A.Kennedy, J.Ryans, et al. Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1-G93A ALS mouse model. PLoS One. 2014;9:e96921.
4. J.Shefner, J.M.Cedarbaum, M.E.Cudkowicz, et al. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13:430–8.
5. J.Shefner, A.Wolff, L.Meng The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:582–5.
6. J.M.Shefner, M.L.Watson, L.Meng, A.A.Wolff, N.C.S.Team A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:574–81.
7. B.R.Brooks, R.G.Miller, M.Swash, T.L.Munsat, World Federation of Neurology Research Group on Motor Neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
8. M.Cudkowicz, L.van den Berg, J.Shefner, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomized, double-blind, phase III trial. Lancet Neurol. 2013;11:1059–67.
9. J.D.Berry, J.M.Shefner, R.Conwit, et al. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One. 2013;8: e61177.
10. L.Dupuis, R.Dengler, M.T.Heneka, et al. A randomized, double-blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One. 2012;7:e37885.
11. T.Lenglet, L.Lacomblez, J.L.Abitbol, et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol. 2014;21:529–36.
12. U.K.-L.S.Group, K.E.Morrison, S.Dhariwal, et al. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase III multicentre, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:339–45.
13. R.G.Miller, D.H.Moore, D.A.Forshew, et al. Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology. 2011;77:973–9.
14. S.P.Aggarwal, L.Zinman, E.Simpson, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:481–8.
15. P.Kaufmann, J.L.Thompson, G.Levy, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66:235–44.
16. V.Meininger, V.E.Drory, P.N.Leigh, A.Ludolph, W.Robberecht, V.Silani Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler. 2009;10:378–83.
17. E.J.Sorenson, A.J.Windbank, J.N.Mandrekar, et al. Subcutaneous IGF-1 is not beneficial in two-year ALS trial. Neurology. 2008;71:1770–5.
18. P.H.Gordon, D.H.Moore, R.G.Miller, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomized trial. Lancet Neurol. 2007;6:1045–53.
19. R.Miller, W.Bradley, M.Cudkowicz, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology. 2007;69:776–4.
20. J.M.Cederbaum, N.Stambler, E.Malta, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessment of respiratory function. Journal of the Neurological Sciences.1999;169:13–21.
21. M.E.Cudkowicz, J.M.Shefner, D.A.Schoenfeld, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology.2003;61:456–64.
22. A.Czaplinski, A.A.Yen, S.H.Appel Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77:390–2.
23. B.J.Traynor, H.Zhang, J.M.Shefner, et al. Functional outcome measures as clinical trial endpoints in ALS. Neurology.2004;63:1933–5.